Physician profile
Chen Li
NPI 1295179257
$4,877.16
in general payments reported to CMS, 2019-2025
23 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $190 · 2021: $315 · 2022: $715 · 2023: $1,028 · 2024: $993 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.81 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $738.61 | 2019-2025 | Kcentra |
| Pfizer INC. | $625.71 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $413.84 | 2023-2025 | Rebyota |
| Janssen Pharmaceuticals, INC | $394.74 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.94 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $362.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $354.21 | 2019-2024 | Dificid, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $275.89 | 2022-2025 | Ultomiris, Soliris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.97 | 2019-2025 | Jardiance |
| Shionogi INC | $265.81 | 2022-2025 | Fetroja |
| Novartis Pharmaceuticals Corporation | $123.41 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $121.15 | 2025 | Vowst |
| E.R. Squibb & Sons, L.L.C. | $109.26 | 2022-2025 | Eliquis |
| Vifor Pharma, INC. | $99.08 | 2022-2023 | Veltassa |
| Vertex Pharmaceuticals Incorporated | $87.31 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $65.58 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $60.10 | 2024 | Nuzyra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.92 | 2025 | Lifevest |
| Insmed, INC. | $26.92 | 2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $23.05 | 2019 | |
| Abbvie INC. | $21.48 | 2021 | |
| Melinta Therapeutics, LLC | $17.01 | 2025 | Rezzayo |
| Mylan Specialty L.P. | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chen Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.